title: Whey and soy protein supplements changes body composition in patients with Crohn's disease undergoing azathioprine and anti-TNF-alpha therapy.
abstract: BACKGROUND
  Crohn's disease (CD) is a chronic transmural inflammation of the gastrointestinal tract of unknown cause. Malnutrition associated with active CD has been reduced although obesity has increased. Dietary strategies such as those with high-protein have been proposed to reduce body fat. This study compares the effects of two supplements on the nutritional status of CD patients.
  
  
  METHODS
  68 CD patients were randomized in two groups: whey protein group (WP) and soy protein group (SP). Using bioimpedance analysis, anthropometry and albumin and pre-albumin dosages the nutritional status was measured before starting the intervention and after 8 and 16 weeks. The disease activity was determined by Crohn's Disease Activity Index and serum C-reactive protein dosage and dietary intake by 24h dietary recalls.
  
  
  RESULTS
  Forty-one patients concluded the study and both supplements changed body composition similarly. Triceps skin fold thickness (p< 0.001) and body fat percentage (p=0.001) decreased, whereas mid-arm muscle circumference (p=0.004), corrected arm muscle area (p=0.005) and body lean percentage (p=0.001) increased.
  
  
  CONCLUSIONS
  For Crohn's disease patients undergoing anti TNF-alpha and azatioprine therapies, supplementation with whey and soy proteins changes body composition through reduction of body fat and thus contributes to control inflammation.
authors: Center for Investigation in Pediatrics, Pediatrics Department, Medical Sciences Faculty, University of Campinas - UNICAMP, Rua Tessália Vieira de Camargo, 126, CEP 13083-970, Campinas, São Paulo, Brazil.. juliafm83@gmail.com.
authors: Júlia Figueiredo
authors: JF
authors: Machado
authors: Center for Investigation in Pediatrics, Pediatrics Department, Medical Sciences Faculty, University of Campinas - UNICAMP, Rua Tessália Vieira de Camargo, 126, CEP 13083-970, Campinas, São Paulo, Brazil.. marluce@fcm.unicamp.br.
authors: Vanessa
authors: V
authors: Oya
authors: Gastrocenter - Coloproctology Unit, Surgery Department, Gastrocenter, Medical Sciences Faculty, University of Campinas, Rua Carlos Chagas, 420, CEP 13083- 878, Campinas - São Paulo, Brazil.. marluce@fcm.unicamp.br.
authors: Cláudio Saddy Rodrigues
authors: CS
authors: Coy
authors: Center for Investigation in Pediatrics, Pediatrics Department, Medical Sciences Faculty, University of Campinas - UNICAMP, Rua Tessália Vieira de Camargo, 126, CEP 13083-970, Campinas, São Paulo, Brazil.. marluce@fcm.unicamp.br.
authors: André Moreno
authors: AM
authors: Morcillo
authors: Center for Investigation in Pediatrics, Pediatrics Department, Medical Sciences Faculty, University of Campinas - UNICAMP, Rua Tessália Vieira de Camargo, 126, CEP 13083-970, Campinas, São Paulo, Brazil.. marluce@fcm.unicamp.br.
authors: Silvana Dalge
authors: SD
authors: Severino
authors: Hilmar Cheese Company, Hilmar, CA, USA.. marluce@fcm.unicamp.br.
authors: Chao
authors: C
authors: Wu
authors: Food Engineering Faculty, University of Campinas - UNICAMP, Rua Monteiro Lobato, 80, CEP 13083-970, Campinas, São Paulo, Brazil.. marluce@fcm.unicamp.br.
authors: Valdemiro Carlos
authors: VC
authors: Sgarbieri
authors: Center for Investigation in Pediatrics, Pediatrics Department, Medical Sciences Faculty, University of Campinas - UNICAMP, Rua Tessália Vieira de Camargo, 126, CEP 13083-970, Campinas, São Paulo, Brazil.. marluce@fcm.unicamp.br.
authors: Maria Marluce dos Santos
authors: MM
authors: Vilela
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects*; D003424:Crohn Disease / Q000178:diet therapy* / Q000188:drug therapy*; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D030262:Soybean Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000067816:Whey Proteins / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D030262:Soybean Proteins; D014409:Tumor Necrosis Factor-alpha; D000067816:Whey Proteins; D001379:Azathioprine